IMNP News 4.3000 Immune Pharmaceuticals Inc. (IMNP)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immune Pharmaceuticals Inc. (IMNP) 4.3000 $IMNP

Immune Pharmaceuticals Announces Company Highlights and Reports Full Fiscal Year 2013 Financial Results
GlobeNewswire - Thu Apr 10, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (Nasdaq:IMNP) ("Immune" or "the Company" announced today company highlights and its financial results for the 12-month period ended December 31, 2013.

Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
Business Wire - Wed Apr 09, 7:23AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind(R) system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook as Chief Financial Officer, filling the position which had been vacant since December 31, 2013. Mr. Cook brings over 20 years of experience in senior finance and management leadership roles in the healthcare and pharmaceutical industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc. (NASDAQ OMX First North and OTCQX:IMNP), a developer of antibody therapeutics for cancer treatment, following its merger with EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX:EPCT).

Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.

Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.

IMMUNE Pharmaceuticals to Present at the 16th BIO CEO & Investor Conference
Marketwire - Thu Feb 06, 4:45PM CST
IMMUNE Pharmaceuticals Inc. (OTCQX: IMNP) (NASDAQ: IMNP) announced today that Daniel Teper, Chairman and Chief Executive Officer, will be presenting at the 16th annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 11:30AM local time at the Waldorf Astoria, Room Duke of Windsor, in New York.

LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals
Marketwire - Tue Dec 10, 7:01AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer. Immune Pharmaceuticals' lead development program is bertilimumab, currently in Phase II clinical trials for treatment of ulcerative colitis (UC), Crohn's disease (CD) and bullous pemphigoid (BP), an orphan, autoimmune dermatological condition. Data from trials of bertilimumab in BP and CD are expected in mid-2014, and data from the UC trial is expected in the first half of 2015.

Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier
PR Newswire Europe - Mon Nov 25, 11:01PM CST
TARRYTOWN, New York and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North" . The Company will transfer its common stock listing from the NASDAQ OMX Stockholm Exchange on November 29, 2013, and the first day of trading on First North will be December 2, 2013.

Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
PR Newswire Europe - Tue Nov 19, 11:02PM CST
-- GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION

Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
PR Newswire Europe - Thu Oct 31, 11:01PM CDT
Immune Pharmaceuticals Inc. announced today that it has appointed Erik Penser Bankaktiebolag as a liquidity provider for the Company's common shares currently listed on NASDAQ OMX Stockholm Exchange under the trading symbol IMNP. The firm will continue to be the Company's liquidity provider after its planned transfer of its stock listing from NASDAQ OMX Stockholm Exchange to NASDAQ OMX First North Premier.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 89

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 52

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 30

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 110

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 102

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 49

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Limina’s Amberflo Deal Makes AI Usage Visible at Scale

Updated Category News Views 26

Enterprise AI has created a billing fog, and Limina just bought itself a flashlight. Its merger with Amberflo, completed on October 30 and announced November 19, brings metering, cost attribution, and billing technology fully inside Limina’s data-governance platform. No price was disclosed, which is irritating but ordinary for a transaction involving companies that do...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 112

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading

Top 5 Most Recently Viewed Articles

Coveo Earns Recognition as Leader in Generative AI Solutions

Updated Category News Views 244

Coveo Achieves AWS Generative AI Competency Coveo, a frontrunner in the field of AI-Relevance, is thrilled to announce its esteemed recognition for achieving the Amazon Web Services (AWS) Generative AI Competency. This designation not only highlights Coveo's exceptional capabilities but also emphasizes its role in helping businesses harness the power of AI to optimize...

Continue Reading
Legal Inquiry Regarding MediaAlpha, Inc. (MAX) Securities Issues

Updated Category News Views 151

Understanding the Securities Investigation of MediaAlpha, Inc. Investors are currently facing a troubling time as MediaAlpha, Inc. (MAX) finds itself under scrutiny. This investigation, brought forth by a prominent law firm, focuses on potential violations of federal securities laws. The significant implication of these allegations has led many investors to seek clarity...

Continue Reading
Rapid Growth in Data Center Liquid Cooling Market Forecasted

Updated Category News Views 159

Overview of the Data Center Liquid Cooling Market The Data Center Liquid Cooling Market has become a crucial focus in modern technology, with its market size projected to rise from USD 2.99 billion to USD 17.28 billion. This significant growth, a Compound Annual Growth Rate (CAGR) of 21.54% from 2024 to 2032, indicates a transitioning landscape in data management...

Continue Reading
Eupraxia Pharmaceuticals Shares Exciting Updates on EoE Trial

Updated Category News Views 327

Eupraxia Pharmaceuticals' Latest Trial Results for EP-104GI Eupraxia Pharmaceuticals Inc. (TSX: EPRX) has reported exciting news regarding its ongoing clinical trial for the treatment of eosinophilic esophagitis (EoE) with EP-104GI. This treatment aims to alleviate symptoms and improve the quality of life for patients suffering from this challenging condition. Highlights...

Continue Reading
Innovative Robotics Solutions Set to Transform Warehousing

Updated Category News Views 253

Revolutionizing Warehouse Operations with Robotics Autonomous forklifts are taking a leap forward by adapting into existing warehouse environments, promising a quick return on investment. The robotics innovator, Riibotics, is poised to present its innovative solutions at RoboBusiness 2025. This event is taking place at the Santa Clara Convention Center, where Riibotics...

Continue Reading